Neuraxis Inc. logo

Neuraxis Inc. (NRXS)

Market Closed
8 Dec, 20:00
AMEX AMEX
$
2. 62
-0.05
-1.87%
$
20.71M Market Cap
- P/E Ratio
0% Div Yield
31,030 Volume
0 Eps
$ 2.67
Previous Close
Day Range
2.54 2.65
Year Range
1.33 6.2
Want to track NRXS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NRXS closed today lower at $2.62, a decrease of 1.87% from yesterday's close, completing a monthly decrease of -3.68% or $0.1. Over the past 12 months, NRXS stock gained 11.49%.
NRXS is not paying dividends to its shareholders.
The last earnings report, released on Nov 24, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on AMEX (USD).

NRXS Chart

Similar

Actinium Pharmaceuticals Inc.
$ 1.4
-2.1%
Maia Biotechnology Inc.
$ 1.23
+2.5%
IGC
IGC Pharma Inc.
$ 0.29
-2.38%
Nanoviricides Inc.
$ 1.43
+16.26%
Kairos Pharma Ltd.
$ 0.87
-2.35%
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth

NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth

NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.

Zacks | 3 weeks ago
NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript

NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript

NeurAxis, Inc. ( NRXS ) Q3 2025 Earnings Call November 11, 2025 9:00 AM EST Company Participants Brian Carrico - President, CEO & Director Timothy Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the NeurAxis Reports Third Quarter 2025 Financial Results Conference Call.

Seekingalpha | 3 weeks ago
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth

NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth

NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.

Zacks | 3 months ago

Neuraxis Inc. (NRXS) FAQ

What is the stock price today?

The current price is $2.62.

On which exchange is it traded?

Neuraxis Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is NRXS.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 20.71M.

Has Neuraxis Inc. ever had a stock split?

No, there has never been a stock split.

Neuraxis Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Brian Carrico CEO
AMEX Exchange
US64134X2018 ISIN
US Country
19 Employees
- Last Dividend
- Last Split
9 Aug 2023 IPO Date

Overview

NeurAxis, Inc. is a pioneering medical technology enterprise focused on the innovation of neuromodulation therapies. These therapies are devised to alleviate chronic and debilitating conditions affecting both children and adults throughout the United States. Initially known as Innovative Health Solutions, Inc., the company underwent a name change to NeurAxis, Inc. in March 2022. Founded in 2011 and headquartered in Carmel, Indiana, NeurAxis, Inc. is at the forefront of offering groundbreaking solutions, significantly enhancing patient care. The company primarily caters to healthcare providers, including hospitals and clinics, distributing its technological advancements widely across the healthcare sector.

Products and Services

Listed below are the products and services offered by NeurAxis, Inc.:

  • IB-Stim:

This is a cutting-edge percutaneous electrical nerve field stimulation system. It's specifically designed for use in younger patients, ranging from 11 to 18 years of age, who suffer from functional abdominal pain associated with irritable bowel syndrome (IBS). The system operates by delivering targeted electrical nerve field stimulation, providing a non-pharmacological treatment option that aims to significantly reduce the symptoms of IBS in this age group. By focusing on such a niche, NeurAxis, Inc. contributes to fulfilling a critical gap in pediatric healthcare solutions.

Contact Information

Address: 11550 North Meridian Street, Carmel, IN, United States, 46032
Phone: (812) 689-0791